Abstract
Purpose
The objective of this short review is to evaluate the efficacy of ferric pyrophosphate
citrate and to determine its place in therapy based on the current published literature.
Methods
A literature search was conducted and pared down to yield 4 placebo controlled Phase
II and III clinically relevant trials.
Findings
Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that
has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous
iron supplementation and to increase serum ferritin concentrations.
Implications
This agent may be administered to patients with stage 5 chronic kidney disease receiving
hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin
saturation, and ferritin concentrations.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Kidney Diseases Improving Global Outcomes: Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf. Accessed July 26, 2015
- Iron management in end-stage renal disease.Am J Kidney Dis. 1997; 29: 319-333
- Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systemic review and meta-analysis.Am J Kidney Dis. 2008; 52: 897-906
- Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.Pharmacotherapy. 2007; 27: 343-350
- Parenteral iron use in the management of anemia in end-stage renal disease patients.Am J Kidney Dis. 2000; 35: 1-12
- Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during dialysis.Kidney Int. 1999; 55: 1891-1898
- Iron transfer from transferrin to ferritin mediated by polyphosphate compounds.Biochim Biophys Acta. 1981; 677: 417-423
- Iron exchange between transferrin molecules mediated by phosphate compounds and other cell metabolites.Biochim Biophys Acta. 1977; 499: 169-177
- Pyrophosphate as a ligand for delivery of iron to isolated rat-liver mitochondria.Biochim Biophys Acta. 1984; 766: 233-239
- Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration?.J Lab Clin Med. 2000; 136: 371-378
- Intravenous iron: from anathema to standard of care.Am J Hematol. 2008; 83: 580-588
- Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.Kidney Int. 2015; 88: 1187-1194
- Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.Nephrol Dial Transplant. 2015; 30: 2019-2026
U.S. National Institutes of Health. http://www.clinicaltrials.gov. Accessed July 6, 2016.
- Chronic administration of iron dextran into the peritoneal cavity of rats.Perit Dial Int. 1997; 17: 179-185
Article info
Publication history
Published online: September 27, 2016
Accepted:
August 29,
2016
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
